Mei Chen Selected Research

Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa)

2/2012	Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.
1/2012	Epidermolysis bullosa acquisita.
3/2011	Congenital epidermolysis bullosa acquisita: vertical transfer of maternal autoantibody from mother to infant.
8/2010	Clinical and immunological heterogeneity of canine subepidermal blistering dermatoses with anti-laminin-332 (laminin-5) auto-antibodies.
12/2008	Familial epidermolysis bullosa acquisita.
1/2008	Autoimmunity to type VII collagen: epidermolysis bullosa acquisita.
10/2007	Autoimmunity to type VII collagen: epidermolysis bullosa acquisita.
6/2007	The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita.
6/2006	Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients.
5/2005	Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mei Chen Research Topics

Disease

70	Neoplasms (Cancer) 10/2022 - 10/2004
35	Inflammation (Inflammations) 01/2022 - 04/2007
25	Epidermolysis Bullosa Dystrophica (Dystrophic Epidermolysis Bullosa) 01/2022 - 01/2002
22	Wounds and Injuries (Trauma) 01/2022 - 03/2007
18	Macular Degeneration (Age-Related Maculopathy) 11/2022 - 04/2007
18	Hypoxia (Hypoxemia) 09/2021 - 10/2004
13	Fibrosis (Cirrhosis) 07/2022 - 02/2012
13	Epidermolysis Bullosa Acquisita (Acquired Epidermolysis Bullosa) 02/2012 - 05/2002
12	Infections 04/2021 - 01/2003
11	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2013
11	Retinal Degeneration 11/2020 - 01/2011
9	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 09/2009
9	Neuroinflammatory Diseases 01/2021 - 05/2010
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 12/2014
8	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 02/2010
6	Retinal Diseases 11/2022 - 01/2008
6	Lung Neoplasms (Lung Cancer) 01/2022 - 11/2013
6	Blister (Bulla) 11/2021 - 05/2005
6	Central Nervous System Cavernous Hemangioma 01/2021 - 02/2009
6	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021 - 08/2014
6	Skin Diseases (Skin Disease) 10/2018 - 10/2007
6	Bipolar Disorder (Manic Depressive Psychosis) 01/2017 - 10/2007
6	Arthritis (Polyarthritis) 01/2016 - 04/2006
6	Bullous Pemphigoid (Pemphigoid) 03/2013 - 07/2004
5	Disease Progression 07/2022 - 04/2013
5	Ischemia 01/2020 - 01/2013
5	Breast Neoplasms (Breast Cancer) 12/2018 - 10/2004
5	Tuberculosis (Tuberculoses) 01/2018 - 10/2003
5	Multiple Myeloma 01/2015 - 04/2012
5	Autoimmune Diseases (Autoimmune Disease) 07/2014 - 07/2004
4	Stomach Neoplasms (Stomach Cancer) 10/2022 - 06/2014
4	Junctional Epidermolysis Bullosa (Epidermolysis Bullosa Letalis) 01/2022 - 08/2010
4	Ganglion Cysts (Ganglion) 06/2021 - 12/2015
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 10/2007
4	Cognitive Dysfunction 01/2021 - 08/2011
4	Carcinogenesis 01/2021 - 03/2015
4	Squamous Cell Carcinoma of Head and Neck 01/2021 - 04/2017
4	Choroidal Neovascularization 01/2020 - 01/2014
4	Hepatocellular Carcinoma (Hepatoma) 05/2018 - 06/2012
3	Dementia (Dementias) 01/2022 - 01/2018
3	Stroke (Strokes) 01/2022 - 11/2006
3	Cicatrix (Scar) 01/2022 - 01/2009
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 05/2019

Drug/Important Bio-Agent (IBA)

38	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2007
35	Retinaldehyde (Retinal)IBA 01/2022 - 01/2008
31	Collagen Type VIIIBA 11/2021 - 01/2002
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2010
14	AutoantibodiesIBA 03/2013 - 06/2002
13	CollagenIBA 07/2022 - 07/2004
11	CytokinesIBA 04/2022 - 09/2003
11	Biological ProductsIBA 07/2021 - 01/2008
11	Messenger RNA (mRNA)IBA 01/2021 - 10/2003
10	Pharmaceutical PreparationsIBA 04/2021 - 05/2002
10	Arachidonic Acid (Vitamin F)IBA 01/2017 - 05/2010
9	EnzymesIBA 01/2022 - 05/2002
8	Immunoglobulin G (IgG)IBA 01/2015 - 05/2002
7	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 11/2016
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020 - 01/2013
6	Complement System Proteins (Complement)IBA 07/2022 - 04/2007
6	RNA (Ribonucleic Acid)IBA 04/2022 - 01/2019
6	Therapeutic UsesIBA 01/2022 - 05/2005
6	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2022 - 03/2007
6	pembrolizumabIBA 01/2022 - 08/2017
6	Long Noncoding RNAIBA 01/2022 - 01/2019
6	LipopolysaccharidesIBA 01/2017 - 05/2010
5	AntibodiesIBA 11/2022 - 05/2002
5	Axitinib (AG 013736)IBA 01/2022 - 01/2019
5	Sunitinib (Sutent)FDA Link 01/2022 - 01/2019
5	Interleukin-17 (Interleukin 17)IBA 11/2021 - 02/2015
5	Interleukin-4 (Interleukin 4)IBA 09/2020 - 01/2003
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2018 - 05/2008
5	Bortezomib (Velcade)FDA Link 01/2015 - 04/2012
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2022 - 03/2010
4	Gentamicins (Gentamicin)FDA LinkGeneric 01/2022 - 08/2017
4	Oxygen (Dioxygen)IBA 12/2020 - 01/2019
4	Peptides (Polypeptides)IBA 01/2020 - 08/2010
4	Nonsense Codon (Nonsense Mutation)IBA 01/2020 - 10/2014
4	MicroRNAs (MicroRNA)IBA 01/2020 - 12/2013
4	ElementsIBA 10/2019 - 10/2008
4	Monoclonal AntibodiesIBA 01/2018 - 07/2004
4	VaccinesIBA 01/2013 - 10/2003
4	Leukotriene B4IBA 10/2012 - 04/2006
4	LithiumIBA 09/2012 - 10/2007
3	Neutralizing AntibodiesIBA 07/2022 - 01/2008
3	Protons (Proton)IBA 01/2022 - 01/2020
3	Protein Isoforms (Isoforms)IBA 01/2022 - 05/2008
3	KalininIBA 01/2022 - 10/2018
3	Lysine (L-Lysine)FDA Link 01/2022 - 12/2018
3	Protein Glutamine gamma Glutamyltransferase 2IBA 01/2022 - 02/2005

Therapy/Procedure

49	Therapeutics 07/2022 - 10/2004
10	Radiotherapy 07/2022 - 10/2018
9	Lasers (Laser) 07/2022 - 02/2013
9	Drug Therapy (Chemotherapy) 01/2022 - 10/2003
5	Immunotherapy 07/2022 - 01/2016
4	Injections 11/2022 - 03/2007
4	Intravitreal Injections 01/2022 - 03/2014
4	Acupuncture Therapy 01/2021 - 06/2011
4	Proton Therapy 03/2020 - 01/2020
4	Photothermal Therapy 01/2020 - 08/2014
3	Precision Medicine 09/2021 - 05/2018